On June 16, 2021 Selecta Biosciences a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, reported that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the Raymond James Human Health Innovation Conference to be held virtually, June 21-23, 2021 (Press release, Selecta Biosciences, JUN 16, 2021, View Source [SID1234584062]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation on Wednesday, June 23 at 12:00 p.m. ET will be available through the Raymond James conference portal and an archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.